Pediatric reauthorization
Executive Summary
Pediatric exclusivity incentives for off-patent drugs are likely to be part of legislation expected in April from Sens. Dodd (D-Conn.) and Dewine (R-Ohio) to reauthorize pediatric provisions in FDA Modernization Act. The bill will likely run for six years to put pediatric provisions on same timeline as the Prescription Drug User Fee Act
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth